10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RASA1 Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP12950b

Specification

RASA1 Antibody (C-term) Blocking peptide - Product Information

Primary Accession P20936

RASA1 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 5921

Other Names
Ras GTPase-activating protein 1, GAP, GTPase-activating protein, RasGAP, Ras p21 protein activator, p120GAP, RASA1, GAP, RASA

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

RASA1 Antibody (C-term) Blocking peptide - Protein Information

Name RASA1

Synonyms GAP, RASA

Function
Inhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1.

Cellular Location
Cytoplasm.

Tissue Location
In placental villi, detected only in the trophoblast layer (cytotrophoblast and syncytiotrophoblast). Not detected in stromal, endothelial or Hofbauer cells (at protein level)

RASA1 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

RASA1 Antibody (C-term) Blocking peptide - Images

RASA1 Antibody (C-term) Blocking peptide - Background

The protein encoded by this gene is located in thecytoplasm and is part of the GAP1 family of GTPase-activatingproteins. The gene product stimulates the GTPase activity of normalRAS p21 but not its oncogenic counterpart. Acting as a suppressorof RAS function, the protein enhances the weak intrinsic GTPaseactivity of RAS proteins resulting in the inactive GDP-bound formof RAS, thereby allowing control of cellular proliferation anddifferentiation. Mutations leading to changes in the binding sitesof either protein are associated with basal cell carcinomas.Alternative splicing results in two isoforms where the shorterisoform, lacking the N-terminal hydrophobic region but retainingthe same activity, appears to be abundantly expressed in placentalbut not adult tissues.

RASA1 Antibody (C-term) Blocking peptide - References

Hemerly, J.P., et al. Eur. J. Endocrinol. 163(5):747-755(2010)Wiemels, J.L., et al. Blood Cells Mol. Dis. 45(3):186-191(2010)Bachas, C., et al. Blood 116(15):2752-2758(2010)Oinuma, I., et al. J. Biol. Chem. 285(36):28200-28209(2010)Anand, S., et al. Nat. Med. 16(8):909-914(2010)